CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

被引：0
|
作者：
Danese, Silvio
Vermeire, Severine
D'Haens, Geert R.
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Lavie, Frederic
Bravata, Ivana
Sloan, Sheldon
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Lowenberg, Mark
Gaya, Daniel
Peyrin-Biroulet, Laurent
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
105
引用
下载
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [1] Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial
    Danese, S.
    Vermeire, S.
    D'Haens, G.
    Panes, J.
    Dignass, A.
    Magro, F.
    Nazar, M.
    Le Bars, M.
    Sloan, S.
    Lahaye, M.
    Ni, L.
    Daperno, M.
    Lukas, M.
    Armuzzi, A.
    Lowenberg, M.
    Gaya, D. R.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S049 - S052
  • [2] EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN'S DISEASE: RESULTS FROM THE STARDUST TRIAL
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    D'Haens, Geert R.
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Le Bars, Manuela
    Lahaye, Marjolein
    Nazar, Maciej
    Ni, Lioudmila
    Bravata, Ivana
    Lavie, Frederic
    Daperno, Marco
    Lukas, Milan
    Armuzzi, Alessandro
    Lowenberg, Mark
    Gaya, Daniel R.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S800 - S800
  • [3] Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial
    Peyrin-Biroulet, L.
    Vermeire, S.
    D'Haens, G. R.
    Panes, J.
    Dignass, A.
    Magro, F.
    Le Bars, M.
    Lahaye, M.
    Nazar, M.
    Ni, L.
    Bravata, I.
    Lavie, F.
    Daperno, M.
    Lukas, M.
    Armuzzi, A.
    Lowenberg, M.
    Gaya, D. R.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I132 - I134
  • [4] Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
    Danese, Silvio
    Vermeire, Severine
    D'Haens, Geert
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Bravata, Ivana
    Lavie, Frederic
    Daperno, Marco
    Lukas, Milan
    Armuzzi, Alessandro
    Lowenberg, Mark
    Gaya, Daniel R.
    Peyrin-Biroulet, Laurent
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 294 - 306
  • [5] Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
    Danese, S.
    Vermeire, S.
    D'Haens, G.
    Panes, J.
    Dignass, A.
    Magro, F.
    Nazar, M.
    Le Bars, M.
    Lahayel, M.
    Ni, L.
    Bravata, I.
    Gaya, D. R.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S032 - S033
  • [6] Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    D'Haens, Geert
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Bravata, Ivana
    Lavie, Frederic
    Daperno, Marco
    Lukas, Milan
    Armuzzi, Alessandro
    Loewenberg, Mark
    Gaya, Daniel R.
    Danese, Silvio
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 175 - 185
  • [7] CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    D'Haens, Geert R.
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Bravata, Ivana
    Lavie, Frederic
    Daperno, Marco
    Lukas, Milan
    Armuzzi, Alessandro
    Lowenberg, Mark
    Gaya, Daniel R.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S801 - S801
  • [8] Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial
    Danese, S.
    Vermeire, S.
    D'Haens, G.
    Panes, J.
    Dignass, A.
    Magro, F.
    Nazar, M.
    Le Bars, M.
    Lahaye, M.
    Ni, L.
    Bravata, I.
    Gaya, D. R.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S330 - S331
  • [9] Analysis of clinical features associated with favourable outcomes from ustekinumab treat-totarget strategy in Crohn's Disease patients in the STARDUST trial
    Danese, S.
    Vermeire, S.
    Dignass, A.
    Panes, J.
    D'Haens, G.
    Magro, F.
    Le Bars, M.
    Nazar, M.
    Lahaye, M.
    Ni, L.
    Bravata, I.
    Gaya, D. R.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S039 - S040
  • [10] PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
    D'Haens, Geert R.
    Adedokun, Omoniyi J.
    Danese, Silvio
    Vermeire, Severine
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Gaya, Daniel R.
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (06) : S694 - S694
12345